TY - JOUR T1 - Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 32 LP - 37 DO - 10.1136/sextrans-2020-054718 VL - 98 IS - 1 AU - Sylvia Kusemererwa AU - Andrew Abaasa AU - Anita Kabarambi AU - Martin Onyango AU - Joseph Okello Mugisha Y1 - 2022/02/01 UR - http://sti.bmj.com/content/98/1/32.abstract N2 - Objectives Participation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.Methods We used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend p<0.05) in the proportion of women reporting risky sexual behaviour or a diagnosed STI between baseline and end of follow-up.Results Between September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. There were decreases in all markers of sexual risk behaviour with statistically significant decreases in only the proportion of women reporting ≥2 sexual partners, p=0.026 and those diagnosed with Trichomonas vaginalis p<0.001 and or Neisseria gonorrhoeae p<0.001Conclusions No evidence of risk compensation was observed in this trial.Trial registration number NCT01539226.Data are available on reasonable request. ER -